The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.


John J. Martin,
Assistant Administrator.

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City


John J. Martin,
Assistant Administrator.

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DOCKET NO. DEA–392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUPPLEMENTARY INFORMATION: The companies listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances.

The company plans to manufacture the listed controlled substances in bulk for conversion to other controlled substances and sale to its customers, for dosage form development, for clinical trials, and for use in stability qualification studies.


John J. Martin,
Assistant Administrator.

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DOCKET NO. DEA–392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of various classes of schedule I or II controlled substances.

The company plans to manufacture the listed controlled substances in bulk for conversion to other controlled substances and sale to its customers, for dosage form development, for clinical trials, and for use in stability qualification studies.


John J. Martin,
Assistant Administrator.

American Radiolabeled Chem

Cerilliant Corporation